Reprogenetics and pharmacogenetics: in whose best interests?

Area of Science:

• Bioethics
• Genetics
• Public Health

Background:

• Reprogenetics, involving pre-implantation genetic diagnosis, raises ethical concerns regarding saviour siblings, eugenics, and genetic enhancement.
• Pharmacogenetics, the study of genetic influences on drug response, is emerging and has implications for public health.
• Genetic epidemiological studies are vital for resource allocation and strategic health planning.

Purpose of the Study:

• To explore the intersection of reprogenetics and pharmacogenetics.
• To examine the potential of these fields in improving public health outcomes and resource management.
• To highlight the commercial potential and the need for robust ethical and legal frameworks.

Main Methods:

• Review of current literature and ethical considerations in reprogenetics and pharmacogenetics.
• Analysis of the impact of genetic information on public health strategies and resource allocation.
• Discussion of commercial implications and the necessity for updated legal safeguards.

Main Results:

• Reprogenetics and pharmacogenetics can identify population-specific medical susceptibilities and guide targeted interventions.
• Pharmacogenetics enables cost-effective prescribing by aligning medications with genetic profiles.
• Both fields present significant commercial opportunities for biotechnology and national economies.

Conclusions:

• Integrating reprogenetics and pharmacogenetics can optimize healthcare resource allocation and improve public health.
• There is a critical need for enhanced ethical and legal safeguards, including informed consent and public participation in policy-making.
• Rethinking legal frameworks is essential to ensure genuine protection and thorough ethical scrutiny of reprogenetic and pharmacogenetic projects.